CD101 is a novel echinocandin with antifungal potency and spectrum similar to those of the three currently approved echinocandins, caspofungin (CSF), micafungin (MCF), and anidulafungin (ANF) (6, 7), and is currently undergoing clinical development as an intravenous (i.v.)formulation for treatment and prevention of candidemia/invasive candidiasis and as a topical formulation for treatment of vulvovaginal candidiasis. This evidence concerns the gene CD101 and Candidiasis, Invasive.